Summary ArmaGen Technologies, Inc. (ArmaGen) is a biotechnology company that research, discovers and develops new therapies for the treatment of neurological disorders. The company's technology platform solutions targets recombinant proteins, therapeutic monoclonal antibodies and siRNA to the brain. ArmaGen's blood-brain barrier protects the brain from bacteria and other foreign substances. The company's pipeline products are used in the treatment of neurological symptoms of lysosomal storage diseases (LSDs) and neurodegenerative diseases such as Alzheimers and Parkinsons. It conducts research in a variety of invasive and non-invasive techniques to deliver therapies. ArmaGen is headquartered in Calabasas, California, the US. ArmaGen Technologies, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector... Research Beam Model: Research Beam Product ID: 343813 250 USD New
ArmaGen Technologies Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile
 
 

ArmaGen Technologies Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • Category : Healthcare
  • Published On : July   2015
  • Pages : 36
  • Publisher : GlobalData
 
 
 
Summary

ArmaGen Technologies, Inc. (ArmaGen) is a biotechnology company that research, discovers and develops new therapies for the treatment of neurological disorders. The company's technology platform solutions targets recombinant proteins, therapeutic monoclonal antibodies and siRNA to the brain. ArmaGen's blood-brain barrier protects the brain from bacteria and other foreign substances. The company's pipeline products are used in the treatment of neurological symptoms of lysosomal storage diseases (LSDs) and neurodegenerative diseases such as Alzheimers and Parkinsons. It conducts research in a variety of invasive and non-invasive techniques to deliver therapies. ArmaGen is headquartered in Calabasas, California, the US.

ArmaGen Technologies, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table Of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 4
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 9
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
ArmaGen Technologies Raises US$17 Million In Series A Financing 10
Licensing Agreements 12
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 12
SULFAMIDASE BRAIN DRUG DELIVERY IN SANFILIPPO SYNDROME 14
METACHROMATIC LEUKODYSTROPHY ENZYME DRUG DEVELOPMENT 15
MANUFACTURING OF TROJAN HORSE-TNFR DECOY RECEPTOR FUSION PROTEIN 16
METACHROMATIC LEUKODYSTROPHY ENZYME DRUG DEVELOPMENT 17
MANUFACTURING OF TROJAN HORSE-TNFR DECOY RECEPTOR FUSION PROTEIN 18
ENZYME REPLACEMENT THERAPY OF THE BRAIN IN MUCOPOLYSACCHARIDOSIS TYPE II 19
METACHROMATIC LEUKODYSTROPHY ENZYME DRUG DEVELOPMENT 20
BIOENGINEERING OF A NEW ANTIBODY DRUG DELIVERY TECHNOLOGY 21
MANUFACTURING OF TROJAN HORSE-TNFR DECOY RECEPTOR FUSION PROTEIN 22
ENZYME REPLACEMENT THERAPY OF THE BRAIN IN MUCOPOLYSACCHARIDOSIS TYPE II 23
IDURONIDASE REPLACEMENT THERAPY OF THE BRAIN IN HURLER'S SYNDROME 24
BIOENGINEERING OF A NEW ANTIBODY DRUG DELIVERY TECHNOLOGY 25
RE-ENGINEERING BLOOD-BORNE ERYTHROPOIETIN FOR TARGETED DELIVERY 26
ENZYME REPLACEMENT THERAPY OF THE BRAIN IN MUCOPOLYSACCHARIDOSIS TYPE II 27
IDURONIDASE REPLACEMENT THERAPY OF THE BRAIN IN HURLER'S SYNDROME 28
BIOENGINEERING OF A NEW DECOY RECEPTOR DRUG DELIVERY TECHNOLOGY 29
TARGETED DELIVERY OF SIRNA FOR INTRAVENOUS RNAI 30
TARGETED PARAOXONASE FUSION PROTEIN AS A NEUROTHERAPEUTIC FOR NERVE GAS AGENTS 31
IDURONIDASE REPLACEMENT THERAPY OF THE BRAIN IN HURLER'S SYNDROME 32
ArmaGen Technologies, Inc. - Key Competitors 33
Key Employees 34
Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List Of Tables
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Key Facts 1
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
ArmaGen Technologies, Inc., Deals By Therapy Area, 2009 to YTD 2015 8
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 9
ArmaGen Technologies Raises US$17 Million In Series A Financing 10
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 12
SULFAMIDASE BRAIN DRUG DELIVERY IN SANFILIPPO SYNDROME 14
METACHROMATIC LEUKODYSTROPHY ENZYME DRUG DEVELOPMENT 15
MANUFACTURING OF TROJAN HORSE-TNFR DECOY RECEPTOR FUSION PROTEIN 16
METACHROMATIC LEUKODYSTROPHY ENZYME DRUG DEVELOPMENT 17
MANUFACTURING OF TROJAN HORSE-TNFR DECOY RECEPTOR FUSION PROTEIN 18
ENZYME REPLACEMENT THERAPY OF THE BRAIN IN MUCOPOLYSACCHARIDOSIS TYPE II 19
METACHROMATIC LEUKODYSTROPHY ENZYME DRUG DEVELOPMENT 20
BIOENGINEERING OF A NEW ANTIBODY DRUG DELIVERY TECHNOLOGY 21
MANUFACTURING OF TROJAN HORSE-TNFR DECOY RECEPTOR FUSION PROTEIN 22
ENZYME REPLACEMENT THERAPY OF THE BRAIN IN MUCOPOLYSACCHARIDOSIS TYPE II 23
IDURONIDASE REPLACEMENT THERAPY OF THE BRAIN IN HURLER'S SYNDROME 24
BIOENGINEERING OF A NEW ANTIBODY DRUG DELIVERY TECHNOLOGY 25
RE-ENGINEERING BLOOD-BORNE ERYTHROPOIETIN FOR TARGETED DELIVERY 26
ENZYME REPLACEMENT THERAPY OF THE BRAIN IN MUCOPOLYSACCHARIDOSIS TYPE II 27
IDURONIDASE REPLACEMENT THERAPY OF THE BRAIN IN HURLER'S SYNDROME 28
BIOENGINEERING OF A NEW DECOY RECEPTOR DRUG DELIVERY TECHNOLOGY 29
TARGETED DELIVERY OF SIRNA FOR INTRAVENOUS RNAI 30
TARGETED PARAOXONASE FUSION PROTEIN AS A NEUROTHERAPEUTIC FOR NERVE GAS AGENTS 31
IDURONIDASE REPLACEMENT THERAPY OF THE BRAIN IN HURLER'S SYNDROME 32
ArmaGen Technologies, Inc., Key Competitors 33
ArmaGen Technologies, Inc., Key Employees 34

List Of Figures
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 1
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 1
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 1
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 6
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
ArmaGen Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter